Unsurprisingly, elevated CD151 expression was linked to poorer clinical outcomes in NSCLC25, 26 whilst preclinical studies have reported the role of CD151 as a tumour promoter in NSCLC.19 Here, CD151 is linked to non-small cell lung carcinoma.